Olin Corp (OLN)

May 7, 2025, 6:13 AM EDT - 7 days ago

Olin: Despite Weak Results, Valuation Is Attractive (Downgrade)

May 2, 2025, 3:30 PM EDT - 11 days ago

Olin Corporation (OLN) Q1 2025 Earnings Call Transcript

May 1, 2025, 4:05 PM EDT - 12 days ago

Olin Announces First Quarter 2025 Results

Apr 18, 2025, 2:05 PM EDT - 25 days ago

Olin - Winchester Completes Acquisition of Small Caliber Ammunition Manufacturing Assets

Apr 17, 2025, 7:30 AM EDT - 27 days ago

Hidrogenii, an Olin and Plug Joint Venture, Commissions 15 Ton Per Day Hydrogen Liquefaction Plant in Louisiana

PLUG

Mar 25, 2025, 4:05 PM EDT - 7 weeks ago

Olin Corporation First Quarter 2025 Earnings Conference Call Announcement

Mar 6, 2025, 6:30 AM EST - 2 months ago

Retired U.S. Army General Edward M. Daly Appointed to Olin's Board of Directors

Mar 2, 2025, 11:00 AM EST - 2 months ago

The Schall Law Firm Invites Shareholders With Losses In Olin Corporation To Join A Securities Fraud Investigation

Feb 28, 2025, 4:05 PM EST - 2 months ago

Olin Announces Pricing of Private Offering of Senior Notes

Feb 28, 2025, 7:40 AM EST - 2 months ago

Olin To Pursue Private Offering of Senior Notes

Feb 18, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Olin Corporation (OLN) And Encourages Shareholders to Reach Out

Feb 18, 2025, 9:29 AM EST - 3 months ago

OLN Investors Have Opportunity to Join Olin Corporation Fraud Investigation with the Schall Law Firm

Feb 17, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Olin Corporation (OLN) and Encourages Shareholders to Learn More About the Investigation

Feb 16, 2025, 10:00 AM EST - 3 months ago

Olin Corporation (OLN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Feb 14, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Olin Corporation (OLN) Shareholders to Inquire about Securities Investigation

Feb 13, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Olin Corporation (OLN) And Encourages Investors to Connect

Feb 12, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Olin Corporation (OLN) Stockholders to Inquire about Securities Investigation

Feb 11, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Olin Corporation (OLN) and Encourages Investors to Learn More About the Investigation

Feb 10, 2025, 10:00 AM EST - 3 months ago

Olin Corporation (OLN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Feb 7, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Olin Corporation (OLN) And Encourages Stockholders to Connect

Feb 6, 2025, 10:00 AM EST - 3 months ago

Olin Corporation (OLN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Feb 5, 2025, 4:05 PM EST - 3 months ago

Groundbreaking Ceremony for State-of-the-Art 6.8mm Ammunition Facility at the Lake City Army Ammunition Plant

Feb 5, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Olin Corporation (OLN) and Encourages Stockholders to Learn More About the Investigation

Feb 4, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Olin Corporation (OLN) Investors to Inquire about Securities Investigation

Feb 3, 2025, 4:00 PM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Olin Corporation (OLN) And Encourages Investors to Reach Out

Jan 31, 2025, 4:29 PM EST - 3 months ago

Olin Corporation (OLN) Q4 2024 Earnings Call Transcript

Jan 30, 2025, 4:05 PM EST - 3 months ago

Olin Announces Fourth Quarter 2024 Results

Jan 27, 2025, 3:00 AM EST - 3 months ago

Swarm Oncology Unveils Highly Differentiated, Personalised T Cell Therapy Platform to Significantly Improve Treatment Outcome for Cancer Patients and Appoints Martin Olin as Chief Executive Officer